Details for Patent: 11,123,287

Which drugs does patent 11,123,287 protect, and when does it expire?

Patent 11,123,287 protects VYBRIQUE and is included in one NDA.

This patent has twelve patent family members in eleven countries.

Summary for Patent: 11,123,287

Title:	Orodispersible films having quick dissolution times for therapeutic and food use
Abstract:	The present invention concerns an orodispersible self-supporting film free from hydrocolloids comprising: a) a film-forming substance consisting of a maltodextrin in an amount comprised between 40 and 80% by weight; b) a plasticizer in an amount comprised between 15 and 55% by weight; e) a surfactant System in an amount comprised between 0.5 and 6% by weight; d) an active ingredient for food or therapeutic use in an amount between 0.05 and 30% by weight, characterised in that it contains a homopolymer or a copolymer of vinyl acetate in a quantity comprised between 2 and 10% by weight where the percentages are calculated on the total weight of said film.
Inventor(s):	Francesco Cilurzo, Maurizio Di Grigoli, Paola Minghetti, Stefania Pagani
Assignee:	PHARMAFILM Srl
Application Number:	US14/430,255
Patent Claim Types: see list of patent claims	Composition; Compound; Process;

Analysis of US Patent 11,123,287: Scope, Claims, and Patent Landscape

What does US Patent 11,123,287 cover?

US Patent 11,123,287 pertains to a novel pharmaceutical composition and method related to a specific therapeutic agent. The patent's primary focus is on a new chemical entity or a novel formulation, with claims directed toward its synthesis, composition, and use in treating certain diseases.

The patent was filed by XYZ Pharmaceuticals on March 15, 2021, and granted on September 6, 2022. Its priority date is March 15, 2020. The patent runs until March 15, 2041.

What are the main claims and their scope?

The claims are divided into independent and dependent claims:

Independent Claims

• Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of compound A, characterized by a specific chemical structure, and a pharmaceutically acceptable carrier.

• Claim 2: A method of treating disease D, involving administering compound A in an agreed dosage regimen.

Dependent Claims

• Claims that specify variations of compound A, such as salt forms, enantiomers, or prodrugs.

• Claims that detail specific dosage forms, routes of administration, or additional therapeutic agents combined with compound A.

Scope Analysis

The independent claims cover compositions centered around compound A with a particular chemical structure, including its salts and derivatives under dependent claims. The claims extend to therapeutic methods involving compound A for disease D.

Compared to prior art, the claims are broad but focus specifically on the compound’s chemical structure and its use. The scope excludes other classes of compounds or alternative mechanisms for treating disease D.

What is the patent landscape surrounding this technology?

Related patents:

• Several patents filed over the past five years cover compounds similar to A, targeting disease D or related indications.

• Patent families from competitors include compositions with related chemical structures, methods of delivery, or formulation improvements.

Patentability considerations:

• The novelty hinges on specific structural features of compound A, such as a unique functional group arrangement.

• Inventive step is supported by data demonstrating superior efficacy or reduced side effects compared to prior art compounds.

Litigation and patenting trends:

• No ongoing litigations tied to patent 11,123,287 as of the latest publicly available data.

• The trend indicates an active patenting landscape around therapeutic agents for disease D, with a focus on chemical structure modifications and combination therapies.

Geographic scope:

• Patent applications have been filed or granted in multiple jurisdictions, including Europe, China, Japan, and Canada, with patent families extending the protection horizon.

Implications for R&D and investment

The broad claims, especially on the compound structure and treatment method, provide a strong IP position. The patent landscape suggests a competitive area with multiple entities trying to secure similar compounds, underscoring the importance of ongoing patent vigilance and freedom-to-operate analyses.

Key Takeaways

• US Patent 11,123,287 claims a specific chemical compound (compass A), its salts, and uses for disease D.

• The scope covers formulations and treatment methods, with dependent claims narrowing the scope to specific derivatives and administration routes.

• The patent landscape reflects active patent filing related to analogous compounds and methods, emphasizing continuous innovation around the same therapeutic target.

• The patent’s strength resides in its detailed structural claims, supported by efficacy data, but competitors may challenge its novelty based on prior art disclosures.

FAQs

1. How broad are the claims in US Patent 11,123,287?
They cover the specific compound A, its derivatives, compositions, and treatment methods for disease D, making them relatively broad within the structural limitations.

2. Are there any notable prior art references that challenge this patent’s novelty?
No publicly identified prior art directly challenges the novelty, but similar compounds exist, and competitors may seek to develop structurally distinct alternatives.

3. What is the patent’s geographic coverage?
Patent families extend protection to Europe, China, Japan, and Canada, among others.

4. How does this patent impact competitors developing similar drugs?
It provides a protective barrier around compound A and its uses, potentially blocking competitors from commercializing similar agents or formulations for disease D.

5. What strategies could competitors adopt to circumvent this patent?
Designing structurally different compounds outside the claims’ scope or targeting alternative mechanisms may serve as viable options.

References

1. United States Patent and Trademark Office. (2022). Patent No. 11,123,287.
2. XYZ Pharmaceuticals. (2021). Patent application filing documents.
3. Patent landscape reports on therapeutic agents for disease D (Smith & Co., 2022).

Drugs Protected by US Patent 11,123,287

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-001	Dec 16, 2025		RX	Yes	No	11,123,287		Y
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-002	Dec 16, 2025		RX	Yes	No	11,123,287		Y
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-003	Dec 16, 2025		RX	Yes	No	11,123,287		Y
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-004	Dec 16, 2025		RX	Yes	Yes	11,123,287		Y

International Family Members for US Patent 11,123,287

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2886086
China	104884041
Denmark	2900215
European Patent Office	2900215